VBI Vaccines Inc (NASDAQ:VBIV) traded down 4.5% during trading on Tuesday . The stock traded as low as $0.81 and last traded at $0.86, 3,722,836 shares were traded during trading. An increase of 122% from the average session volume of 1,678,684 shares. The stock had previously closed at $0.91.
A number of equities research analysts recently weighed in on VBIV shares. Raymond James started coverage on shares of VBI Vaccines in a research note on Thursday, November 14th. They issued an “outperform” rating and a $3.00 target price on the stock. Zacks Investment Research lowered shares of VBI Vaccines from a “buy” rating to a “hold” rating in a research report on Wednesday, August 21st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. VBI Vaccines presently has an average rating of “Buy” and a consensus price target of $3.81.
The firm has a market cap of $160.13 million, a P/E ratio of -0.81 and a beta of 0.79. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.88 and a quick ratio of 1.84. The stock has a 50 day moving average of $0.63 and a 200 day moving average of $0.88.
In other VBI Vaccines news, CEO Jeff Baxter acquired 150,000 shares of the stock in a transaction dated Monday, September 30th. The stock was purchased at an average cost of $0.50 per share, for a total transaction of $75,000.00. Following the acquisition, the chief executive officer now owns 608,255 shares in the company, valued at approximately $304,127.50. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Steven Gillis acquired 10,000,000 shares of the business’s stock in a transaction dated Thursday, September 19th. The stock was acquired at an average cost of $0.50 per share, with a total value of $5,000,000.00. Insiders have bought a total of 30,212,000 shares of company stock worth $15,105,440 over the last quarter. Corporate insiders own 10.50% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. General American Investors Co. Inc. boosted its position in VBI Vaccines by 23.2% during the second quarter. General American Investors Co. Inc. now owns 2,174,264 shares of the biopharmaceutical company’s stock valued at $2,544,000 after buying an additional 409,800 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of VBI Vaccines in the second quarter worth about $25,000. Bank of Montreal Can lifted its stake in shares of VBI Vaccines by 71.8% in the 2nd quarter. Bank of Montreal Can now owns 37,604 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 15,717 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of VBI Vaccines by 664.5% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 200,848 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 174,576 shares during the last quarter. Finally, Fosun International Ltd boosted its holdings in VBI Vaccines by 43.6% during the 2nd quarter. Fosun International Ltd now owns 1,051,126 shares of the biopharmaceutical company’s stock valued at $1,156,000 after acquiring an additional 319,045 shares during the period. Institutional investors own 40.91% of the company’s stock.
About VBI Vaccines (NASDAQ:VBIV)
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
Read More: Technical Analysis
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.